



1 **Supplementary figures and figure legends**



2

3 **Figure S1 Unsupervised clustering of ferroptosis regulators of patients with OSCC**

4 (A–E) Consensus matrices of 463 patients with OSCC (GSE41613, GSE42743, TCGA-
5 OSCC) (k = 2–5). (F) GSVA enrichment analysis showing the different activation states
6 of biological pathways associated with the ferroptosis regulation patterns. Ferroptosis
7 cluster A vs. ferroptosis cluster C. Heat map: blue, activated pathways; red: inhibited
8 pathways. The different cohorts served as sample annotations.
9
10



11

12 **Figure S2 Characteristics of immune-cell infiltration, TME signature, immune**
 13 **checkpoint, and chemokine transcriptomes of distinct gene clusters**

14 (A–E) Consensus matrices of the TCGA-OSCC data (k = 2–5). (F) The enrichment scores
15 of immune-cell infiltrations in three ferroptosis gene clusters. (G) The enrichment score of
16 the TME signature of three ferroptosis gene clusters. (H) Immune-checkpoint-relevant
17 genes and immune-activation-relevant genes expressed in three ferroptosis gene clusters.
18 Significant differences among of three ferroptosis clusters were assessed using the
19 Kruskal–Wallis test (ns: not significant, *P < 0.05, **P < 0.01, ***P < 0.001).

20

21

22

23

24

25

26


27

28

29

30

31



32

33 **Figure S3 Significance of the FPscore in determining the roles of the outcomes**


34 (A) Kaplan–Meier PFI curves for high and low FPscore subtype in the TCGA-OSCC
 35 cohort (log-rank test, $P = 0.005$). (B) Kaplan–Meier analysis of DSS of the high and low
 36 FPscore subtypes in the TCGA-OSCC cohort (log-rank test, $P = 0.003$). (C, D) Kaplan–
 37 Meier analysis of the OS of high and low FPscore subtype in the GSE42743 cohort (log-
 38 rank test, $P = 0.037$) and GSE41613 cohort (log-rank test, $P = 0.003$).

39

40

41

42



57

58 **Figure S5 Time-dependent ROC curve of the immunotherapy cohorts**

59 (A–E) Time-dependent ROC curves for predicting OS of the independent immunotherapy
 60 cohort, including IMvigor210, GSE91061, TCGA-SKCM, Gide et al. cohort, and
 61 GSE78220.